A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
The $6.6bn of M&A deals announced by drug makers in third quarter of 2018 marks the slowest three-month period since 2013.
A return to tuck-in deals – sort of.
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
After a slow 2017, first-quarter biopharma acquisition activity could signal a turnaround.
Biopharma acquisitions slump in 2017, but venture capital-backed buyouts provide hope.
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.